Data as of Aug 25, 2026 · Based on 3,181,687 AI responses across 10,525 prompts · See how Parse measures this
Glycomine is developing GLM101, a mannose-1-phosphate replacement therapy for the rare genetic disease PMM2-CDG. The company is currently enrolling participants in a global Phase 2b clinical trial to evaluate the drug's safety and efficacy.
Parse Score